Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30893589 | 0.80 | NOS3 (0.41) | OGAKDM4EALDH1A1 | |
| SCHEMBL10282500 | 0.80 | NOS3 (0.41) | OGAKDM4EALDH1A1 | |
| SCHEMBL5018922 | 0.78 | GABRA1 (0.44) | OGAMAPK1KDM4EALDH1A1TP53 | |
| SCHEMBL2231397 | 0.78 | KDM4E (0.40) | GCKMAPK1KDM4E | |
| SCHEMBL826949 | 0.77 | PDE10A (0.55) | PDE10AMMP2MMP9MMP8 | |
| SCHEMBL27499514 | 0.77 | ALDH1A1 (0.39) | OGAPDE10AKDM4ENTRK1ALDH1A1 | |
| SCHEMBL9385487 | 0.77 | ALDH1A1 (0.39) | OGAPDE10AKDM4EALDH1A1 | |
| SCHEMBL3970945 | 0.77 | ALDH1A1 (0.39) | OGAPDE10AKDM4EALDH1A1TP53 | |
| SCHEMBL24176501 | 0.76 | OGA (0.41) | OGAKDM4EALDH1A1TP53 | |
| SCHEMBL13034790 | 0.76 | ALDH1A1 (0.53) | OGAPDE10AMAPK1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220125786-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200283430-A1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-7893020-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | OGA 30/4885GCK 341/4885PDE10A 970/4885 |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | OGA 66/4885GCK 422/4885PDE10A 2433/4885 |
| US-20220125786-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | OGA 30/4885GCK 341/4885PDE10A 970/4885 |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | OGA 66/4885GCK 422/4885PDE10A 2433/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | OGA 839/4885GCK 2973/4885PDE10A 3554/4885 |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | OGA 30/4885GCK 341/4885PDE10A 970/4885 |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | FXR1, NR1H2, NR1H4 | OGA 3543/4885GCK 1686/4885PDE10A 1694/4885 |
| US-20200283430-A1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H2, NR1H4 | OGA 3543/4885GCK 1686/4885PDE10A 1694/4885 |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | OGA 30/4885GCK 341/4885PDE10A 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.